NT 501

Drug Profile

NT 501

Alternative Names: Ciliary neurotrophic factor - Neurotech; Ciliary neurotrophic factor implant - Neurotech; CNTF implant - Neurotech; Encapsulated CNTF - Neurotech; NT-501; Retinitis pigmentosa encapsulated cell therapy - Neurotech; Rexenus

Latest Information Update: 05 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Neurotech USA
  • Developer National Eye Institute; Neurotech USA; Stanford University; University of Miami
  • Class Cell therapies; Eye disorder therapies
  • Mechanism of Action Ciliary neurotrophic factor replacements; Neurogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinal telangiectasis; Retinitis pigmentosa
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Retinitis pigmentosa
  • Phase II Glaucoma; Retinal telangiectasis; Usher syndromes
  • Phase I/II Colour vision defects
  • Phase I Optic nerve disorders
  • No development reported Dry macular degeneration

Most Recent Events

  • 20 Jun 2017 Efficacy and adverse events data from a phase II trial in retinal (macular) telangiectasia released by Neurotech Pharmaceuticals and Lowy Medical Research Institute
  • 22 May 2017 Neurotech Pharmaceuticals completes a phase-II trial in Retinal telangiectasis in USA, Australia (NCT01949324)
  • 12 May 2017 Neurotech Pharmaceutical initiates a phase II extension trial for Retinal telangiectasia in USA and Australia (NCT03071965)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top